Patents by Inventor Dave Keng Boon WEE

Dave Keng Boon WEE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense oligonucleotides
    Patent number: 11072795
    Abstract: The present invention relates to antisense oligonucleotides for modulating the activity of glycine decarboxylase (GLDC). In particular, the present invention relates to antisense oligonucleotides capable of inducing exon skipping of RNA. Also claimed are pharmaceutical compositions, kits and methods of treating cancer and inducing exon-skipping using said antisense oligonucleotides. In addition, a method for aiding the categorising or determining prognosis of a cancer or in selecting a therapeutic strategy for a patient with cancer, based on assessing the level of GLDC nucleic acid, protein or activity in a sample derived from the patient is provided.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: July 27, 2021
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Uttam Surana, Dave Keng Boon Wee, Jing Lin, Bing Lim
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING THE FUNCTION OF A T CELL
    Publication number: 20200377883
    Abstract: The present invention relates to antisense oligonucleotides for modulating the function of a T cell, including antisense oligonucleotides that hybridise to IFN-?, granzyme, perforin 1, PD-1, PRDM1, PD-L1, CD40LG, NDFIP1, PDCD1 LG2, REL, BTLA, CD80, CD160, CD244, LAG3, TIGIT, ADORA2A & TIM-3 RNAs. In particular, the present invention relates to antisense oligonucleotides capable of inducing exon skipping of RNA. Also claimed is a method for further modifying the specificity of said T-cell by providing for a T cell receptor gene.
    Type: Application
    Filed: June 27, 2018
    Publication date: December 3, 2020
    Inventors: Ernest GUCCIONE, Dave Keng Boon WEE, Antonio BERTOLETTI